---
document_datetime: 2025-03-28 14:50:45
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/winrevair-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: winrevair-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1923658
conversion_datetime: 2025-12-26 10:04:47.055741
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Winrevair

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 28/03/2025                          |                                             | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000246288   | PRODUCTS - C.I.z Other variation - Accepted C.I.z (IB) - To update the Product Information to: -remove reference to section 5.3 in section '4.2 Posology and method of administration' of SmPC as it is not relevant to the paediatric population; -clarify the information on disposal measures as the local requirements can be different in each EU Member State; -update the image details/positioning in the mock-ups for cartons and in the Instructions for Use (1 vial/2 vial), in accordance with the mock-ups reviewed and approved by the Agency. - update the list of local representatives. Furthermore, the Marketing Authorisation Holder has taken the opportunity to implement editorial corrections in the local translations.   | Labelling and PL   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|